From a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...

As we see a recovery in the market, it is good to be cognizant of the fact that more than the narratives on the street, it is the earnings ...

Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...

Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...

The Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...

Indian pharma and chemical companies at CPHI Milan say the China+1 opportunity is real, but a “missing middle” in the MSME ecosystem, marke...

Indian equities traded nearly flat after a sharp rally in the previous session, with IT stocks extending gains while pharma shares declined...

JioBlackRock Flexi Cap Fund made complete exits from 18 stocks, including Eternal and Ashok Leyland, in September 2026, while trimming stak...

Kiran Mazumdar-Shaw emphasized the importance of building an innovation-driven pharmaceutical industry in India. She highlighted the need f...

India's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabil...

The company is developing a platform to find simpler, cheaper and more efficient ways to make chemicals, said cofounders Poorvank Purohit a...

Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push f...

The Centre plans to significantly change the regulations governing animal experimentation. The proposed rules aim to allow institutional et...

At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...

Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...

Anupam Rasayan India Ltd anticipates significant growth in its pharmaceutical segment over the next three years. The company expects pharma...

Small and mid-sized Indian pharmaceutical firms are witnessing a shift in orders away from China. As Western buyers diversify their supply ...